459 related articles for article (PubMed ID: 30347344)
1. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
3. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
4. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
6. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
7. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
[TBL] [Abstract][Full Text] [Related]
8. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
10. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
11. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
13. Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.
Zhang M; Lei D; Peng B; Yang M; Zhang L; Charles MA; Rye KA; Krauss RM; Johns DG; Ren G
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Dec; 1862(12):1606-1617. PubMed ID: 28911944
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Murín J; Pernický M; Kiňová S
Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Goldberg AS; Hegele RA
Drug Des Devel Ther; 2012; 6():251-9. PubMed ID: 23055695
[TBL] [Abstract][Full Text] [Related]
16. Future of cholesteryl ester transfer protein inhibitors.
Rader DJ; deGoma EM
Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
[TBL] [Abstract][Full Text] [Related]
17. Rationale for cholesteryl ester transfer protein inhibition.
Hewing B; Fisher EA
Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614
[TBL] [Abstract][Full Text] [Related]
18. The end of the road for CETP inhibitors after torcetrapib?
Joy T; Hegele RA
Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Mabuchi H; Nohara A; Inazu A
Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
[TBL] [Abstract][Full Text] [Related]
20. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
Ferri N; Corsini A; Sirtori CR; Ruscica M
Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]